Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
Season 6, Episode 7, Apr 16, 2023, 11:00 AM
What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
To learn more about biosimilars to treat RA, click here.
To learn more about rheumatologists’ perceptions about RA biosimilars, click here.
To learn more about incentives for prescribing biosimilars, click here.
To learn more about infliximab biosimilar adoption, click here.
To learn more about the influx of adalimumab biosimilars to the US market, click here.
To learn more about ustekinumab biosimilars, click here.
To learn more about rheumatologists’ perceptions about RA biosimilars, click here.
To learn more about incentives for prescribing biosimilars, click here.
To learn more about infliximab biosimilar adoption, click here.
To learn more about the influx of adalimumab biosimilars to the US market, click here.
To learn more about ustekinumab biosimilars, click here.